Regen BioPharma Discloses Dilutive Settlement, Auditor Change, and Super-Voting Preferred Stock
RGBP sits 55% above its 52-week low of $0.
Summary
Regen BioPharma disclosed a court-approved settlement that could massively dilute existing shareholders, created a super-voting preferred stock, and changed auditors — all while facing a going concern warning.
Key Events · Legal and Risk Events · RGBP
-
Dilutive Settlement Approved
Court approved issuance of shares to settle $398,740 in claims; estimated fair value of shares is $697,795, potentially requiring billions of new shares at current prices.
-
Super-Voting Preferred Stock Created
Board authorized 1,000 shares of Series N Preferred Stock, each with 75 million votes — effectively consolidating voting control.
-
Auditor Change
BCRG Group dismissed and Simon & Edward LLP appointed as new independent auditor effective July 13, 2026; no disagreements reported.
-
Financial Distress Context
Company already under going concern warning with critically low cash; this settlement adds significant dilution pressure.
Analysis · RGBP · Life Sciences
Regen BioPharma, already under severe financial distress with a going concern warning, has entered into a court-approved settlement requiring the issuance of shares to satisfy $398,740 in claims. The estimated fair value of shares to be issued is approximately $697,795, which at the current stock price of $0.000155 would represent roughly 4.5 billion shares — more than 10 times the 402.9 million shares outstanding as of April 2026. This massive dilution is compounded by the simultaneous creation of a new Series N Preferred Stock with 1,000 shares, each carrying 75 million votes, effectively giving the board control over all shareholder matters. Additionally, the company dismissed its auditor BCRG Group and appointed Simon & Edward LLP, though no disagreements were reported. The auditor change, while not contentious, adds uncertainty amid the company's precarious financial position.
At the time of this filing, RGBP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $79.4K. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.